R&D Capabilities

Research and Development
group-section left-side-heading-component

We are at the vanguard of life science and healthcare, supported by cutting-edge technology and alliances with significant entities that promote our R&D efforts. With these capabilities and several high-value and high-growth medicines, we are developing a strong product pipeline and speeding up filings for growth to take the lead in the global markets. At our R&D facility, a group of 35 scientists works to improve the health of humanity. Additionally, we are focusing on complex and specialty generic products to ease the lifestyle.

R&D Capabilities
about-overview-healthcare left-side-heading-component
Key Objectives

R&D is working on various dosage forms, focusing on innovative and cutting-edge drug delivery systems for global markets for Solid orals, Liquids, and Parental formulation. Our product development focus is primarily on specialty pharmaceuticals with the FTL process.

Zuventus has been using R&D to make successful inroads in market segments dominated by technology-protected brands.

The technologies developed through large teams of scientists include

  • Matrix/reservoir-based release systems.
  • Multiple Unit Pellets system with Wruster technique for extended-release formulations.
  • Pelletization Technology with the latest processing equipment like extruder & spheronizer and fluid bed processor.
  • Bioavailability enhancement systems based on solubilisation, complexation, and solid dispersion technique.
  • Nano-particle technology-based products.
  • Taste masking technologies for solid and liquid orals.
  • Orodispersible and effervescent technology for solid orals.
  • Synthesis of Ferrous Ascorbate to enhance the effectiveness of iron therapy (Feronia XT) has helped us to attain dominant positions in respective markets.
about-overview-domestic-market left-side-heading-component pb-0
Why R&D and its role?

R&D is crucial for businesses since it offers insightful knowledge to improve current procedures and lower costs while boosting productivity.

R & D developing new products with innovative technology creates uniqueness and differentiation in the market.

Scientific understanding of the product and advanced manufacturing methodology helps for the quality and safety of the product.

Current brand leaders in the market (Source: AIOCD-AWACS) for which R & D has developed products are Augpen, Eslo, Bevon, Zostum, Myotop, Soventus, Maxtra, Feronia, Merotec, Coralium D 3, Rabifast, Cortimax.

Integrating novel viewpoints and methodologies into the formulation process can significantly enhance the appeal and desirability of products among patients, resulting in heightened market demand and value.

Utilizing new packs and packing materials improves the stability of the product and makes the product robust and valuable in terms of quality.

R & D developed product gets registered in the export market which creates a new way forward for the organization's growth.



R&D Center at C-10(12) Ground Floor
Expertise & Specializations of R&D department:

We at Zuventus R&D have a pool of 35 Research Scientists. Scientists hold postgraduate and doctoral degrees in pharmaceutical science and science.

Handling sophisticated and essential equipment like HPLC, UPLC, Gas chromatography, and GCMS is a specialty of analytical scientists. Compression machines, fluidized bed processors, automated coating machines, Speroniser & extruders, ampoule filling machines, viscometers, rapid mixer granulators, and hot melt extruders are all things that formulation scientists are skilled at using.

The microbiology section provides R&D testing, product development, method development, and technology transfer for Scale at the plant level. We have expertise in product development and design.

The area of microbiology includes:

  • Research and development testing.
  • Product development.
  • Technique development.
  • Technology transfer for scale-up at the plant level.

Product development and design are areas in which we excel. Our expertise extends to production, pilot, and lab scales. Additionally, we are skilled in solid oral, liquid oral, parenteral, and external preparation design. In addition, we have experience performing product development using Qbd techniques. In addition to knowledge transfer operations for Scale at the plant level, method development for all products created at the R&D level was carried out.

about-overview-main-objectives left-side-heading-component
Innovative Findings That Have Emerged from These Projects:

1.0 Solid Dispersion Technologies for Solubility & Bioavailability Enhancement: -

  • Solid dispersion formulation is one of the most promising and practical approaches in the pharma industry for increasing the solubility & bioavailability of poorly water-soluble & poor permeability drugs.
  • Cost-effective technology.
  • It improved patient convenience & compliance.

2.0 MUPS Technology for Delayed-Release formulations: -

  • Rapid and uniform transit of subunits contained in tablets from the stomach into the small intestine owing to their small size, drug release is more consistent, and the possibility of dose dumping avoided with a minimized tendency for intersubject variations.
  • Tablets have less difficulty in oesophageal transport than capsules.
  • Tablets containing coated subunits can be prepared at a lower cost than these subunits filled into hard gelatin capsules because of the higher production rate of the tablet press.
  • Cost-effective technology.
  • It improved patient convenience & compliance.

3.0 Pelletization Technology for Delayed Release & Prolonged Release formulations by using extruder spheronizer & Fluid Bed Processor: -

  • Enhancement of drug dissolution; ease of coating; sustained, controlled, or site-specific delivery of the drug from coated pellets; uniform packing; even distribution in the G.I. tract; and less G.I. irritation.
  • Pellets are less susceptible to dose dumping.
  • It reduces the accumulation of drugs especially proven advantageous in the case of irritating drugs.
  • Pellets disperse freely in G.I.T., invariably maximizing drug absorption and reducing peak plasma fluctuation.
  • It improves the safety and efficacy of a drug.

4.0 Bilayer tablet technologies for incompatible fixed dose combination of drugs:

  • Bilayer technology is used as an extension of conventional technology.
  • To prolong the life cycle of fixed-dose combination.
  • The bilayer technology is used for the separation of incompatible components.
  • Increased efficacy due to the synergistic effect of two or three different drugs.
  • Retain potency and ensure dose accuracy.
  • Chemically, mechanically and microbiologically, tablets are very stable.
  • A bi-layer tablet should have the chemical and physical stability to maintain its physical attributes over time.
  • The bi-layer tablet must be able to release the medicinal agents in a predictable and reproducible manner.
  • Better patient compliance is achieved due to its ease of administration.
  • Cost-effective.

5.0 Taste Masking Technology for Bitter Drugs:

  • It does not affect the bioavailability of the drug
  • It has fewer steps and is thus easy to manufacture
  • Better taste gives pharmaceuticals a market advantage
  • It does not affect the bioavailability of the drug
  • It has fewer steps and is thus easy to manufacture
  • The cost of taste-masking a drug is very low
  • The raw materials required for taste masking are relatively less
  • Better taste gives pharmaceuticals a market advantage

6.0 Effervescent & Orodispersible Tablet Technologies for rapid onset of Action:

  • Simple to use. Effervescent is a simple option for those who dislike tablets or have difficulty swallowing tablets (dysphagia).
  • Pleasant taste.
  • Gentle on the stomach.
  • Increases your water intake.
  • Better bioavailability.

7.0 Lyophilization Technology for Injectables:

  • Samples were processed in aseptic conditions.
  • Does not use heat.
  • Less heat ensures sample (drug) stability.
  • Increases shelf life.
  • Samples can be stored at room temperature indefinitely.
  • Reduces weight and volume of samples; ideal for shipping.

8.0 Peptide drug delivery:

  • Peptide-based drugs have great potential applications as therapeutic agents since they have higher efficacy and lower toxicity than chemical drugs.
  • Favorable Pharmacodynamic characteristics comprise high binding affinities, high selectivity and specificity, and good efficacy, generally achieved by peptides due to their larger size and higher number of hydrogen (H)-bond interactions.

9.0 Probiotics:

  • Probiotics Help Balance the Friendly Bacteria in Your Digestive System.
  • Probiotics Can Help Prevent and Treat Diarrhea.
  • Probiotic Supplements Improve Some Mental Health Conditions.
  • Certain Probiotic Strains Can Help Keep Your Heart Healthy.
  • Probiotics May Reduce the Severity of Certain Allergies and Eczema.
  • Probiotics Can Help Reduce Symptoms of Certain Digestive Disorders.
  • Probiotics May Help Boost Your Immune System. Probiotics May Help You Lose Weight and Belly Fat

The above different key technologies impact the company's products, services, or industry as a whole:

  • The above technology-oriented products refer to the value a company gains from its name recognition compared to a market.
  • Brand products have three basic components: consumer perception, negative or positive effects, and the resulting value.
Brand products directly impact sales volume and a company's profitability because consumers gravitate toward products and services with great reputations.